HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

rilmenidine (Hyperium)

Subscribe to New Research on rilmenidine

structure in first source

Also Known As:

Hyperium; 2-(N-(dicyclopropylmethyl)amino)oxazoline; 2-(N-(dicyclopropylmethyl)amino)oxazoline phosphate salt; Biopharma brand of rilmenidine phosphate; S 3341; S-3341; S-3341-3; S3341; oxaminozoline; rilmenidine phosphate; 2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro-

Networked: 140 relevant articles (17 outcomes, 35 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Azoles: 413
    - Oxazoles: 5
      - rilmenidine: 140

Experts

1.	Abdel-Rahman, Abdel A: 6 articles (01/2008 - 09/2003)
2.	Head, Geoffrey A: 3 articles (03/2014 - 01/2003)
3.	Head, G A: 3 articles (01/2010 - 06/2000)
4.	Burke, S L: 3 articles (01/2010 - 06/2000)
5.	Esler, M: 3 articles (07/2004 - 06/2000)
6.	Nikolic, Katarina: 2 articles (01/2016 - 05/2013)
7.	Srdic-Rajic, Tatjana: 2 articles (01/2016 - 05/2013)
8.	Gemovic, Branislava: 2 articles (01/2016 - 05/2013)
9.	Veljkovic, Nevena: 2 articles (01/2016 - 05/2013)
10.	Chung, H H: 2 articles (08/2013 - 09/2012)

Related Diseases

1.	Hypertension (High Blood Pressure) 01/01/2006 - "Improvement in QoL was not related to reduction of BP. Monotherapy with rilmenidine is safe and effective in BP treatment and significantly improves QoL in perimenopausal women with essential hypertension." 02/24/1988 - "Rilmenidine as single therapy appears to be effective and well accepted in the management of mild to moderate hypertension, in particular at the 1-mg/day dose, which normalized 84% of mild hypertensive patients and did not induce any significant adverse effects compared with placebo." 12/09/1995 - "This pharmaco-epidemiologic study showed that the benefit/acceptability ratio for rilmenidine is quite satisfactory and confirms the contribution of rilmenidine as first line treatment for hypertension." 01/01/2009 - "Although the baroreflex-induced RSNA maximum was increased by stress only in hypertensive animals, rilmenidine was effective in minimizing the reflex autonomic disturbances produced by hypertension and stress." 01/01/1995 - "Rilmenidine is a novel oxazoline derivative that is effective in the treatment of hypertension. "
2.	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 01/01/2003 - "The study also examined the effects of 2-year rilmenidine monotherapy on left ventricular hypertrophy (LVH) and on diastolic function of the left ventricle, along with the effects of rilmenidine on left ventricular mass index in hypertensive patients with no LVH, and the relationship between BP reduction and any change in LVH. " 06/01/2000 - "In the at-risk hypertensive, rilmenidine reduces left ventricular hypertrophy to a similar degree to other reference agents. " 01/01/1995 - "We assessed the effects of satisfactory long-term treatment with rilmenidine, a new oxazoline with a potent antihypertensive action, on cardiovascular structural abnormalities and cardiac endocrine function in hypertensive patients with left ventricular hypertrophy. " 01/01/1995 - "Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass." 12/22/1994 - "Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients."
3.	Stroke (Strokes) 11/01/1996 - "1. This study sets out to examine the effect of rilmenidine administered systemically on basal and reflexly activated renal nerve activity in Wistar and stroke prone spontaneously hypertensive rats (SHRSP). " 02/24/1988 - "In contrast to the results obtained at the dose of 50 micrograms/kg, there was no significant variation in pulmonary arterial pressure, cardiac index or stroke index after administration of 25 micrograms/kg. No significant variation was observed in heart rate, sinus function, conduction parameters or atrial, nodal and ventricular refractory periods after administration of 25 and 50 micrograms/kg. Rilmenidine, after single oral administration at the 25 micrograms/kg dose, led to a significant reduction in blood pressure and peripheral resistance without any significant change in cardiac output; the 25- and 50-micrograms/kg doses led to no alteration in heart rate and cardiac electrophysiology." 10/15/1998 - "In the present study we investigated the chronopharmacological dependence of dose-dependent hypotensive and cardiochronotropic effects of the imidazoline-like drugs (clonidine, rilmenidine and moxonidine) in stroke-prone spontaneously hypertensive rats (SHR-SP), using radio-telemetric system (Data Sciences, USA). "
4.	Renal Insufficiency (Renal Failure) 09/18/1989 - "It showed stable plasma concentrations of rilmenidine during a six-month treatment in hypertensive patients with renal insufficiency, reflecting the absence of accumulation of the drug." 09/18/1989 - "Rilmenidine plasma concentrations reached steady state the fifth day at the latest and were related to the degree of renal insufficiency. " 09/18/1989 - "Acceptability of rilmenidine and long-term surveillance of plasma concentrations in hypertensive patients with renal insufficiency." 02/24/1988 - "These relations allow the evaluation of the predicted steady-state level of rilmenidine for a given degree of renal failure. " 09/18/1989 - "Acceptability and plasma concentrations of rilmenidine, a new antihypertensive agent mainly eliminated via the kidney, were evaluated in 17 hypertensive patients (supine diastolic blood pressure, 104 +/- 3 mmHg) with renal insufficiency (creatinine clearance, 35 +/- 4 ml.minute-1/1.73 m2; range, 12 to 58). "
5.	Myocardial Ischemia (Ischemic Heart Diseases) 01/01/2003 - "The intracisternal administration of clonidine (1 microg/kg) and rilmenidine (30 microg/kg) or of a nonhypotensive dose of rilmenidine (3 microg/kg) decreased the incidence of myocardial ischemia (25, 14 and 25%, respectively, versus 60% in controls) and reduced the mortality rate from 40% to 0.0, 0.0 and 12%, respectively. " 01/01/2003 - "We also compared the effects of clonidine and rilmenidine with those of propranolol, a beta-blocker, known to induce protective cardiovascular effects in patients with ischemic heart disease. "

Related Drugs and Biologics

1.	rilmenidine (Hyperium)
2.	Insulin (Novolin)
3.	Clonidine (ST 155)
4.	Glucose (Dextrose)
5.	Perindopril
6.	Atenolol (Tenormin)
7.	Nifedipine (Adalat)
8.	Adiponectin
9.	Blood Glucose (Blood Sugar)
10.	Losartan (Cozaar)

Related Therapies and Procedures

1.	Oral Administration
2.	Intravenous Infusions
3.	Denervation
4.	Intravenous Injections
5.	Renal Dialysis (Hemodialysis)